Kraig Biocraft Laboratories' Monster Silk(TM) Pilot Production Program Enters Second Stage Ahead of Schedule
February 04 2013 - 4:05PM
Kraig Biocraft Laboratories, Inc. (KBLB) (the "Company" or "Kraig")
announced today that it is accelerating its pilot production
program, as a result of positive initial data from the first stage
of the trial.
The acceleration to the second phase of the program is designed
to increase production capacity of Monster Silk™, the Company's
recombinant spider silk, by more than tenfold over the first stage.
Kraig's strategy calls on further accelerating the production
program by initiating a third stage, if the program continues to
meet its targets.
The first phase of the pilot production program for Monster
Silk™ is continuing, even as phase two is being launched. The
purpose of the program is to verify scalability and favorable
production economics of Monster Silk™, to significantly increase
production, and to form the basis of large scale commercial
production of the Company's recombinant spider silks.
"The initial success of the first stage has given us the
confidence to accelerate the program," said Kraig founder and CEO,
Kim Thompson. "We are now well ahead of the schedule that we
envisioned even a few weeks ago. This is a critical step
forward in the commercializing of our laboratory
discoveries. The launching of stage two, which I view as the
heart of the pilot production program, is the most exciting and
momentous event in the Company's history, second only to our
invention of Monster Silk™."
About Kraig Biocraft Laboratories, Inc.
Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com) is a fully
reporting biotechnology company that has achieved a series of
scientific breakthroughs in the area of spider silk technology with
implications for the global textile industry.
Cautionary Statement Regarding Forward Looking Information
Statements in this press release about the Company's future and
expectations other than historical facts are "forward-looking
statements." These statements are made on the basis of management's
current views and assumptions. As a result, there can be no
assurance that management's expectations will necessarily come to
pass. These forward-looking statements generally can be identified
by phrases such as "believes," "plans," "expects," "anticipates,"
"foresees," "estimated," "hopes," "develops," "researching,"
"research," "potential," "could" or other words or phrases of
similar import. Similarly, statements in this release that describe
the Company's business strategy, outlook, objectives, plans,
intentions or goals should all be considered forward-looking
statements. All such forward-looking statements are subject to
certain risks and uncertainties that could cause actual results to
differ materially from those in forward-looking statements.
Management cautions that its ability to further its research, and
create commercially-viable products may be affected by the
competitive environment, the Company's financial condition and its
ability to raise sufficient capital to meet the financial
obligations of its business plan and to fund its continuing
operations.
This press release does not constitute an offer to sell or the
solicitation of an offer to buy any security and shall not
constitute an offer, solicitation or sale of any securities in any
jurisdiction in which such offer, solicitation or sale would be
unlawful prior to registration or qualification under the
securities laws of such jurisdiction.
CONTACT: Ben Hansel, Hansel Capital, LLC.
(720) 288-8495
benhansel@yahoo.com
Kraig Biocraft Laborator... (QB) (USOTC:KBLB)
Historical Stock Chart
From May 2024 to Jun 2024
Kraig Biocraft Laborator... (QB) (USOTC:KBLB)
Historical Stock Chart
From Jun 2023 to Jun 2024